Navigation Links
Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
Date:1/8/2009

al Scientist Training Program; Grass, Helen Hay Whitney, Alfred P. Sloan, March of Dimes, and Klingenstein Foundations and the National Institutes of Health (NIH). He has been or is currently on editorial boards for multiple scientific journals. He currently sits on scientific advisory boards for Novartis and Cellular Bioengineering, Inc.

Dr. Andrew Tager is an Assistant Professor at Harvard Medical School in the Pulmonary and Critical Care Unit of the Massachusetts General Hospital, and co-director of the hospital's interstitial lung disease program. His research is focused on understanding pulmonary inflammation, lung injury and idiopathic pulmonary fibrosis (IPF). Recently Dr. Tager's laboratory published a seminal paper demonstrating that the lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. The results suggested that lysophosphatidic acid is the chemoattractant predominantly responsible for recruiting fibroblasts into the lungs of IPF patients.

Peppi Prasit, Amira Pharmaceuticals' CSO, commented, "We are delighted to have these three renowned scientists join our advisory board. Amira has an outstanding group of scientific advisors who bring complementary skills and experience to our drug discovery and development programs."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the phospholipid pathways. Amira has a strategic partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for effi
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
2. Amira Pharmaceuticals Appoints First Vice President of Development
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress supplier ... special occasion outfits, unveils 65 new bridesmaid dresses ... discounted prices, up to 80% off. , Yunx.co.uk’s dresses ... fashionable designs, gorgeous looks and delicate craftsmanship. These new ... devoted to designing and offering high-quality women’s dresses with ...
(Date:12/24/2014)... December 24, 2014 Mike Billings ... down with Derek Fenwick, PT, MBA, GCS, Director ... will stem from the passing of the Improving ... Act). In this taping of the Infinicast, the two ... of the Social Security Act to standardize post-acute assessment ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... C infection does not contribute to mental decline in people ... have made it possible for people with HIV to survive ... swings and other types of mental impairment as they age, ... with other viruses -- a common problem in people with ... suspects has been the hepatitis C virus, which infects about ...
(Date:12/24/2014)... (HealthDay News) -- Adults who experienced childhood abuse ... headaches, suggests a study published online Dec. 24 ... maltreatment can have long-lasting effects, like associated medical ... author Dawn Buse, director of behavioral medicine at ... in a journal news release. "When managing ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... HEIGHTS, N.J., Oct. 27 Authentidate,Holding Corp. ... of secure workflow,management software and web-based services, ... healthcare agency, has implemented Authentidate,s,Inscrybe Healthcare service ... its extensive customer base in both Ohio ...
... virtually no gastrointestinal, side effects for people who need ... ... CHICAGO, Oct. 27 Announced today at the American,Dietetic ... offers both heme (protein-based iron) and non-heme,iron (plant-based iron) ...
... Frost & Sullivan is,pleased to present the ... Innovation Award to Lifeblood Medical. This is,in recognition ... a,myriad of advantages and has led to the ... solution. In addition to human,organ preservation, Lifeblood Medical,s ...
... to be Used in Early Lines of,Therapy, ... Resources, WALTHAM, Mass., Oct. 27 ... and advisory firms focusing on pharmaceutical and,healthcare ... the leading biologic for Crohn,s disease, but,Abbott/Eisai,s ...
... Across States, WASHINGTON, Oct. 27 Sixty-three percent ... Survey,indicated they have implemented Leapfrog,s Never Events Policy which,describes ... error --,that should never happen to a patient -- ... 2007, the policy,s first year., Leapfrog,s hospital survey ...
... November 1, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Researchers analyzed ... and 22,863 adults,who received transplantation to determine the best ... posttransplant,mortality caused by differences in donor type was vastly ...
Cached Medicine News:Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 2Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 3Health News:WILLCARE Chooses Authentidate's Inscrybe(TM) Healthcare Service to Streamline Operations and Enhance Business Growth 4Health News:First-Ever Over-the-Counter Dual Action Iron Supplement Launched at the American Dietetic Association Conference in Chicago; Bifera to be Available in Select Stores in Early 2009 2Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 2Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 3Health News:Frost & Sullivan Recognizes Lifeblood Medical for Its Innovation in Organ Preservation and Development of the Lifor(R) Solution 4Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:More Hospitals Adopting Leapfrog Group's 'Never Events' Policy Which Inculdes Apologies, Reporting, and Waiving Costs 2Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... 2014  Commonwealth Cornerstone Group (CCG) today announced the completion ... Tuesday to help fund the expansion and consolidation of healthcare ... Sharon . PHN is the largest ... . It is the largest employer in Sharon,s ... on staff. Currently, PHN Sharon offers scattered services ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Reportlinker.com announces that a new ... its catalogue: European ... Suppliers http://www.reportlinker.com/p0651441/European-Chemical-Market-Strategic-Assessments-of-Leading-Suppliers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug ... chemical industry executives with strategically significant ...
... Oct. 5, 2011 Reportlinker.com announces ... is available in its catalogue: ... Strategic Assessments of Leading Suppliers ... This report provides industry executives ...
Cached Medicine Technology:European Chemical Market: Strategic Assessments of Leading Suppliers 2European Chemical Market: Strategic Assessments of Leading Suppliers 3European Chemical Market: Strategic Assessments of Leading Suppliers 4European Chemical Market: Strategic Assessments of Leading Suppliers 5European Chemical Market: Strategic Assessments of Leading Suppliers 6European Chemical Market: Strategic Assessments of Leading Suppliers 7European Chemical Market: Strategic Assessments of Leading Suppliers 8Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 2Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 3Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 4Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 5Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 6Global Oncology Drug Market: Strategic Assessments of Leading Suppliers 7
Adjustable Velcro© closures at crown and behind the neck distinguish this immediate post-op face and chin garment for maximum support and compression....
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Medicine Products: